To confirm that high POSTN and MDK expression is associated with targeted therapy resistance, we performed an RNAscope assay for POSTN and MDK on melanoma tumors in a separate patient cohort (cohort 2, Figure 2C; Table S1) where patients were grouped according to fast progression versus slow progression disease after start of targeted therapy. The gene discussed is MDK; the disease is melanoma.